Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A
✍ Scribed by André Eckardt; Christian Kuettner
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 168 KB
- Volume
- 25
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Background:
Gustatory sweating is a common complication of parotid surgery. injection of botulinum toxin a has been reported as a safe and effective treatment option for patients with frey's syndrome.
Patients and methods:
A total of 69 patients who had undergone superficial parotidectomy because of adenoma were evaluated with respect to the incidence of frey's syndrome and treatment interest. minor's iodine starch test was used to detect the affected skin area. affected skin areas were documented using a digital camera; skin areas were evaluated morphometrically. a single injection of botox per 1 cm(2) skin field was administered to those patients interested in treatment.
Results:
Of 43 patients (62%) with gustatory sweating, 33 patients requested treatment. the affected skin area varied from 16 cm(2) to 81 cm(2). the individual botox dosage ranged from 16 to 80 iu. all relevant clinical symptoms of sweating disappeared within 1 week after a single injection. treatment was well tolerated with no side effects.
Conclusion:
Botox a injection is a safe and effective treatment with long-lasting effects for patients with extensive gustatory sweating.
📜 SIMILAR VOLUMES
## Background: Frey syndrome was first described by baillarger in 1853. frey provided a detailed analysis and description as "auriculotemporal syndrome" in 1923. according to the literature, even the most recent therapeutic measures described for the treatment of patients with frey syndrome have li
## Abstract ## Background First bite syndrome is the development of pain in the parotid region after the first bite of each meal and can be seen after surgery of the parapharyngeal space. The purpose of this study is to evaluate the efficacy of intraglandular injection of botulinum toxin type A (B